Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ASN-51 by Asceneuron for Alzheimer's Disease: Likelihood of Approval
ASN-51 is under clinical development by Asceneuron and currently in Phase II for Alzheimer's Disease. According to GlobalData, Phase II...